NFL Biosciences SA and Diverchim are announcing that they have set up a partnership. Diverchim will manage the production of liquid protein extracts from tobacco and cannabis leaves, which are the core components of NFL-101, NFL Biosciences? botanical drug candidate for the treatment of tobacco addiction, and NFL-201, for treating cannabis dependence. The partnership between NFL Biosciences and Diverchim will involve manufacturing the active ingredient for NFL-101 for its use in additional clinical trials beyond the current CESTO II study (Phase II/III). The development plan mapped out will also cover the preclinical development of the active ingredient of NFL-201, NFL Biosciences? drug candidate for treating cannabis addiction. NFL-101 is a nicotine-free botanical drug candidate, comprising natural proteins extracted from tobacco leaves. It is in Phase II /III clinical trials. NFL-101 is covered by two patent families and has been subject to preclinical and Phase I clinical trials with heavy smokers, highlighting a significant reduction in the desire to smoke and long-term success with stopping smoking, without any toxicity. NFL-101 is derived from an extract with a proven track record on an off-label basis treating more than 10,000 smokers. NFL-201 is a future drug candidate for treating dependence on cannabis, which is frequently consumed alongside tobacco, as well as alcohol. The psychoactive molecule THC and CBD will be removed from the extract during the manufacturing process, in the same way that nicotine is removed from the tobacco leaf extract for NFL-101.